c-myb activation by insertional mutagenesis in murine myeloid leukemias can lead to amino (NH 2 )-terminal or carboxyl (COOH)-terminal truncation of its protein product. We observed that in these leukemias, the steady state level of the protein truncated at the COOH terminus was remarkably higher than that of the protein truncated at the NH 2 -terminus or full length wild-type protein. To examine the rate of proteolysis of dierent forms of Myb in a uniform cellular background, the proteins were constitutively expressed in the myeloblast cell line M1, using the retrovirus vector LXSN. In pulse chase experiments, using metabolically 35 S-labeled proteins, it was determined that COOH-terminal truncation of c-Myb by 248 aa (CT-c-Myb) substantially increases protein stability, resulting in a t 1/2 of about 140 min, as compared to 50 min for full length c-Myb (FL-c-Myb). In an investigation of the mechanism involved in the in vivo degradation of this short lived transcription factor, inhibitors of the lysosomal (chloroquine), proteasomal (ALLM, ALLN, lactacystin) and calpains (EGTA, E64d, BAPTA/AM) pathways were utilized. Results of this experiment identi®ed the 26S proteasome as a major pathway responsible for rapid breakdown of the protein in hematopoietic cells. Further experiments carried out in vitro demonstrated that c-Myb can be ubiquitinated, suggesting that this process may be involved in the targeting of wild-type c-Myb to degradation by the 26S proteasome. In addition, it was demonstrated that CT-cMyb was less eciently ubiquitinated than wild-type protein indicating that defects in modi®cation account for its escape from rapid turnover. We speculate that the increased half-life of c-Myb resulting from truncation could contribute to its transforming potential.
Introduction
The proto-oncogene c-myb encodes a highly conserved nuclear transcription factor which is expressed predominantly in tissues and cells of hematopoietic origin and functions in proliferation and differentiation (for review see LuÈ scher and Eisenman, 1990; Introna et al., 1994) . Functional analyses of deletion mutants have localised three major domains within the c-Myb protein, a DNA binding domain, a transactivation domain (TA) and a negative regulatory domain (NRD). The DNA binding region, responsible for sequence-speci®c binding to DNA, resides in the amino-terminal part of the protein and comprises three imperfect repeats R1, R2 and R3 (Klempnauer and Sippel, 1987; Biedenkapp et al., 1988; Sakura et al., 1989; Howe et al., 1990) . The fact that the centrally located TA domain is hydrophilic and slightly acidic (Nishina et al., 1989; Weston and Bishop, 1989; Ibanez and Lipsick, 1990 ) places cMyb in a large class of transcription factors that have a similar weakly de®ned structure. Its transactivation activity can be modulated by a large NRD at the carboxyl-terminus (Sakura et al., 1989 , Kalkbrenner et al., 1990 , although de®ned components within the NRD, such as the leucine zipper structure and a phosphorylation site at S528, have also been implicated individually in the negative regulation of this function (Hu et al., 1991; Kanei-Ishii et al., 1992; Aziz et al., 1995) . Oncogenic activation of c-Myb in myeloid leukemias has invariably resulted in truncation of the protein at its amino (NH 2 )-terminus or carboxyl (COOH)-terminus or both (for review see Introna et al., 1994) however, it is still not clear what role these truncations play in leukemogenesis.
A common feature of c-Myb and other nuclear transcription factors, involved in the regulation of proliferation and dierentiation of cells, is their short half-life in vivo (Rogers et al., 1986) . Regulated proteolytic degradation provides very eective and irreversible control over the steady state level of such factors in the cell. A previous study showed that c-Myb is metabolically very unstable being rapidly degraded in an ATP-dependent manner (LuÈ scher and Eisenman, 1988) , however, the enzyme(s) or proteolytic pathway involved in its degradation have not been identi®ed.
Recent data suggest that the changes in the stability of proteins encoded by nuclear proto-oncogenes and tumor suppressor genes can substantially in¯uence their transforming activity (Crook and Vousden, 1992; Ciechanover et al., 1994; Papavassiliou et al., 1992; Treier et al., 1994; Stancovski et al., 1995; Tsurumi et al., 1995) . For this reason, we chose to evaluate the truncated leukemia-speci®c forms of cMyb produced in murine promonocytic leukemias for their altered turnover rates. Pulse chase experiments in leukemic cell lines revealed a signi®cantly increased half-life for c-Myb protein, which was truncated at the COOH-terminus, compared with full-length c-Myb or proteins which were truncated at the NH 2 -terminus. This dierence was con®rmed by similar experiments carried out in the M1 myeloblastic cell line, ectopically expressing the truncated forms of Myb, suggesting that decreased sensitivity of the COOH terminally truncated c-Myb toward proteolytic processing is a structural feature of this protein. In additional experiments we identi®ed the 26S proteasome/ubiquitin system as a major mechanism involved in the degradation of wildtype c-Myb.
Results

Expression of c-Myb protein in murine promonocytic leukemias
In murine promonocytic leukemias oncogenic activation of the c-myb gene is achieved frequently by integration of retrovirus in the 5' end of the gene (Shen-Ong and Wol, 1987; Wol et al., 1991; Mukhopadhyaya and Wol, 1992) . This results in replacement of the endogenous c-myb promotor by the viral LTR, ensuring a high level transcription initiation (See Figure 1a , cell lines 30A2-1-2, 30A2-3-12, 30A2-3-14) . In these instances of 5' integration, constitutive transcriptional control is further assured because the virus integrates downstream of a transcriptional pause site found in the ®rst intron of the gene. An alternative type of activation occurred in promonocytic leukemia, R1-4-11, whereby the virus integrated in exon 9 causing premature termination of c-myb transcription ( Figure 1a ). All these insertional mutagenic events are associated with protein truncations at either the NH 2 -terminus (removal of 47 or 71aa) or the COOHterminus (removal of 248 aa). Interestingly, an immunoprecipitation analysis of 35 S-methionine/cysteine labeled c-Myb proteins in murine promonocytic leukemia cell lines revealed that the steady state levels of the tumor speci®c forms were not the same, and as shown in Figure 1b , the protein expressed at the highest level was that which was truncated at the COOH-terminus. This result was rather surprising because the level of c-myb-speci®c mRNA is lower in this cell line compared to cell lines having undergone the more common LTR promotor insertional mutagenesis (see Figure 1a ) and this truncation removed almost 50% of all methionine and cysteine residues that contributed to the radioactive signal in the full-length protein.
Stability of truncated c-Myb protein in murine leukemic cell lines
The dierences observed in steady state level of truncated forms of c-Myb in leukemic cell lines could be explained either by dierent translational efficiencies of these abnormal c-myb-speci®c RNAs or by dierent protein turnover rates. To test the second possibility, we performed a pulse-chase experiment using the 30A2-1-2 leukemic cell line, which expresses a c-Myb truncated at the NH 2 -terminus by 71 aa and the R1-4-11 cell line, which expresses a c-Myb truncated at the COOH-terminus by 248 aa. In addition, we included in this experiment another myeloblastic cell line, NFS 60, because it expresses another COOH-terminally truncated form of c-Myb (truncated by 240 aa) (Weinstein et al., 1986) . The cells were labeled with [ 35 S]methionine/cysteine for 45 min and chased for 30 to 120 min. As shown in Figure 2 , proteins truncated at the COOH terminus had signi®cantly increased half-lives of 110 min (NFS60) and greater than 120 min (R1-4-11) compared to the 38 min half-life of NH 2 -truncated c-Myb in 30A2-1-2 cells. These results provided evidence that the higher steady state level of these forms in promonocytic leukemia cells is a consequence of increased resistance to the proteolytic degradation. constructed the retroviral vectors as described in Materials and methods. The replication defective viruses were produced in GP+E86 cells, an ecotropic packaging cell line and infection of M1 cells was carried out by cocultivation of mitomycin C treated, virus-producing GP+E86 cells for 2 days, followed by selection in medium containing G418 (500 mg/ml). The expression of c-Myb was determined for selected massinfected cultures by immunoprecipitation of protein from labeled total cell lysates (data not shown). To determine the half-lives of truncated proteins in this cellular system, cells were labeled with [
35 S]methionine/ cysteine for 45 min (pulse) and chased in complete medium for dierent lengths of time. As shown in the example in Figure 3 , truncation of the NH 2 -terminus by 47 or 71 aa did not have a signi®cant eect on the protein turnover, whereas truncation of the COOHterminus resulted in a notably more stable protein.
These results together with pulse chase experiments in R1-4-11 and NFS60 cells indicate that the loss of COOH-terminal sequences during leukemogenesis renders c-Myb more resistant to cellular proteolysis. Values in the half-lives, averaged from two independent experiments, demonstrated that CT-c-Myb is 2.8-fold more stable than FL-c-Myb (see Figure 4 ).
Eect of dierent protease inhibitors on the stability of c-Myb protein in vivo
A previous report showed that degradation of c-Myb like another nuclear transcription factor, c-Myc, was an energy-dependent non-lysosomal process (LuÈ scher and Eisenman, 1988) . However, the nature of the proteolytic system responsible for rapid turnover of these transcription factors was not identi®ed. The availability of inhibitors of proteolytic enzymes capable of penetrating cellular membranes allowed us to study the eects of these compounds on c-Myb turnover in intact cells. M1 cells were labeled with [ 35 S]methionine/cysteine and chased as previously described. The inhibitors of dierent proteolytic pathways were added at the indicated concentrations for the last 15 min of the pulse and kept throughout the chase. At the indicated time points, c-Myb protein was immunoprecipitated, separated by polyacrylamide gel electrophoresis and analysed by¯uorography ( Figure 5 ). The intensity of labeled protein decreased rapidly in control cells and cells treated with chloroquine, an inhibitor of the lysosomal proteolytic pathway, and with EGTA, BAPTA/AM and E-64d, inhibitors of calpains. In contrast, the treatment with the peptide aldehydes ALLM and ALLN resulted in the remarkable suppression of c-Myb turnover. Quantitative analyses of the gels (data not shown) revealed that in control cells the intensity of c-Myb speci®c band decreased to 15% of the initial level after a 120 min chase, while in cells treated with peptide aldehydes, ALLM and ALLN, 60 ± 80% of the protein was still present. Taken together these results strongly implicate the involvement of 26S proteasome in the catabolism of c-Myb. Recently it was reported that both peptide aldehydes (ALLM, ALLN), when utilized at this concentration (100 mM) can eectively inhibit not only 26S proteasome, but calpains and lysosomal cathepsin B as well (Rock et al., 1994) . However, unlike calpains and cathepsin B, which are inhibited with equal potency by both peptides, the 26S proteasome is inhibited more potently by ALLN than ALLM (Rock et al., 1994) . As shown in Figure 6 , ALLM was ineective at a concentration of 10 mM while ALLN still substantially inhibited proteolysis. In addition we investigated the eect of 26S proteasomespeci®c inhibitor lactacystin on the c-Myb turnover in M1 cells. As shown in Figure 7 , treatment of M1 cells [min] 
Ubiquitination of c-Myb
Many proteins are post-translationally modi®ed by the addition of ubiquitin molecules as a prerequisite for targeted proteolysis by the 26S proteasome (for recent review Ciechanover, 1994; Hochstrasser, 1995) . Some preliminary results suggested that c-Myb might be modi®ed by ubiquitin in vivo. For example, we noticed that in long exposures of gels from pulse chase analyses there were ladders of slower migrating protein species (data not shown). In addition, we observed some accumulation of these higher molecular mass c-Mybrelated proteins in pulse chase experiments with the inhibitors of 26S proteasome which disappeared together with proteolytic degradation of c-Myb (data not shown). However, we were unable to detect these forms directly by using anti-ubiquitin antibody because of their low abundance in the cells and the poor reactivity of commercially available antibodies against multiubiquitin chains attached to the proteins. Therefore, we carried out in vitro experiments to determine if c-Myb protein can be modi®ed by covalent attachment of ubiquitin. For this purpose, we prepared 35 Smethionine labeled FL-c-Myb protein by coupled in vitro transcription and translation of c-myb cDNA in rabbit reticulocyte lysates. This reaction produced two very closely migrating products. The smaller one was probably initiated from a second methionine at position 21 in murine c-Myb protein since this product completely disappeared when NT1-c-Myb cDNA was used as a substrate. FL-c-Myb was then incubated with cytoplasmic extract from M1 cells as a source of ubiquitin conjugating enzymes in either the presence or the absence of excess exogenously added bovine ubiquitin. As seen in Figure 8 , there was a substantial time-dependent accumulation of slower migrating forms of FL-c-Myb in the reaction with exogenously added ubiquitin. In its absence there was only a slight increase of higher molecular weight forms which was probably due to the presence of residual ubiquitin molecules in M1(S100) cytoplasmic extracts. To con®rm that these high molecular forms are really ubiquitin-modi®ed forms of FL-c-Myb, we immunoprecipitated FL-c-Myb from an in vitro translation reaction using polyclonal rabbit anti GST-c-Myb(I) antiserum immobilized on the Staphylococcus aureus. Immobilized immune complexes were subjected to the ubiquitination reaction as previously described. At the indicated time points an aliquot of the reaction was diluted 100 times with PBS and immune complexes were pelleted by centrifugation and analysed by Western blotting using monoclonal anti-c-Myb or anti-ubiquitin antibody and the ECL detection system (see Material and methods). The results of this experiment are shown in Figure 9 . During this time course, there was an increased accumulation of anti-cMyb reactive bands which migrated above the unmodi®ed FL-c-Myb protein creating a typical stepladder of ubiquitin-modi®ed proteins which was also detected with anti-ubiquitin antibodies. The dierence in mobility of ubiquitin modi®ed c-Myb forms detected by Western blotting (Figure 9 ) and directly by¯uorography (Figure 8 ) is most likely due to less ecient transfer of highly modi®ed c-Myb and also to the blocking of epitopes by long poly-ubiquitin chains. In a control experiment using anti-c-Myb serum for immunoprecipitation in the absence of cMyb protein, we did not detect similar anti-c-Myb immunoreactive bands (data not shown). These experiments demonstrate that full-length c-Myb protein can be ubiquitinated at least in vitro and suggest that this post-translational modi®cation may play an important role in rapid turnover of c-Myb in vivo.
Since, it was previously demonstrated that increased stability of oncogenic versions of the cellular transcription factors c-Fos and c-Jun is a consequence of decreased post-translational modi®cation by ubiquitin (Treier et al., 1994; Stancovski et al., 1995) , it was of interest to determine the extent of in vitro ubiquitination of NH 2 -and COOH-terminally truncated c-Myb proteins. For this purpose, we prepared 35 S-methionine labeled NT1-c-Myb and CT-c-Myb using the rabbit reticulocyte system as described previously. Again, as in the case of FL-c-myb, in vitro translation of CT-cmyb resulted in the production of two major forms of CT-c-Myb. Removal of the ®rst 47 aa from the NH 2 -terminus (NT1-c-myb) resulted in the production of only one major product of expected size. All three forms of c-Myb protein were subjected to in vitro ubiquitination using an increased concentration of M1 (S100) cell lysates to achieve maximal processing of c-Myb proteins. As demonstrated in Figure 10 , FL-c-Myb and NT1-c-Myb were both eciently modi®ed by ubiquitin. In contrast, the appearance of slower migrating forms of CT-c-Myb during the same time course was signi®cantly reduced; only a small proportion of original signal could be detected in the higher molecular forms after 30 mins of incubation in the presence of ubiquitin. These results correlate well with the increased stability of CT-c-Myb compared to fulllength or NH 2 -terminally-truncated forms of c-Myb.
Discussion
Like many regulatory proteins, c-Myb is metabolically very unstable with a half-life of less than 1 h in both avian and murine hematopoietic cells (LuÈ scher and Eisenman, 1988; Foos et al., 1992 ; present study). Presumably, this type of fast turnover provides a rapid o switch when this transcription factor is no longer required in the cell and it is conceivable that changes in the stability of the protein, which could result in inappropriate expression, might have an impact on its role in cellular processes. Interestingly, we demonstrate here that a myeloid leukemia-speci®c form of the protein, having a COOH-terminal truncation of 248 amino acids, was signi®cantly more stable than the normal full length c-Myb protein. Such a change in its protein stability increases the time that c-Myb is present in the cell so it is possible that this protein is more ecient at promoting proliferation and might have a transformation (reviewed by Introna et al., 1994) . Truncations at the COOH-terminus and ranging from 198 to 278 aa have occurred repeatedly as a result of the oncogenic activation of c-myb suggesting that S-methionine labeled c-Myb proteins were incubated in M1 (S100) cell lysates with ubiquitin under ubiquitin-conjugating conditions described in the text and analysed at the indicated times by SDS ± PAGE and¯uorography. The mobility of prestained molecular weight standards (kDa) and the origin (ori) of the electrophoresis gel are marked on the left of the autoradiogram this type of truncation can increase transforming capacity. Indeed, Gonda and coworkers have demonstrated, using an in vitro transformation assay in fetal liver cells, that cells infected with virus expressing a COOH-terminally truncated form of c-Myb showed a higher level of transformation when cultured at low densities than cells infected with viruses expressing wild-type c-Myb (Ferraro et al., 1995) . Although experiments conducted in our laboratory did not uncover dierences in capacities of truncated forms of c-Myb and normal c-Myb to eect proliferation or phenotypic maturation of granulocytic and monocytic cells, the high level of LTR driven expression of myb in these experiments may have masked the subtle eects of COOH-terminal truncation (Bies et al., 1995; Wol et al., 1996) . The high level of expression, as utilized in these dierentiation studies, mimics the promotor insertion mechanism of activation which has been observed in murine myeloid leukemias with virus integration sites at the 5' end of c-myb; for these leukemias we believe LTR promotor driven transcription to be the major activating event. In leukemias that have integrations in the central region of c-myb and causing COOH-terminal truncation, promotor insertion does not play a role (Mukhopadhyaya and Wol, 1992) , therefore, alterations in protein structure which could aect stability might contribute to the transforming capacity of c-Myb.
The concept that the increased stability of the oncogenic form of transcription factors could contribute to enhanced transforming potential has been supported by other recent studies. The escape from ubiquitination and subsequent slower turnover of vJun as compared to c-Jun, for example, has been correlated with increased transforming ability. The key change in the oncogenic form of the protein is loss of the 27 aa d domain demonstrated to be a degradation signal in the wild-type protein (Treier et al., 1994) . The viral form of the Fos protein (v-Fos) is also more stable than its normal counterpart (Papavassiliou et al., 1992; Stancovski et al., 1995) . Interestingly, the targeted degradation of c-Fos is dependent upon a phosphorylation-dependent signal on its transcription partner c-Jun (Papavassiliou et al., 1992; Tsurumi et al., 1995) . Alterations in the regulation of proteolysis has also been shown to in¯uence the oncogenic nature of at least one tumour suppressor, p53. There is evidence to suggest that the E6 protein encoded by high risk human papilloma virus (HPV), associated with cervical carcinomas, is able to interact with p53, an event that leads to an increased rate of p53 degradation (Schener et al., 1990) . Since p53 is involved in negatively regulating progression through the cell cycle, its more rapid degradation would presumably result in reduced control of cell growth.
An outcome of the present study was identi®cation of the 26S proteasome as the major proteolytic complex responsible for the rapid turnover of c-Myb in vivo. Since this proteolytic system is ATP-dependent, our result is consistent with the observation of LuÈ scher and Eisenman (1988) that degradation of c-Myb protein is an ATP-dependent process. The 26S proteasome is large multisubunit complex which usually recognizes and degrades proteins that contain covalently linked multi-ubiquitin chains (for recent reviews see Ciechanover, 1994; Hochstrasser, 1995) . In vitro experiments in this study showed that the FL-cMyb can be modi®ed by ubiquitination (see Figures 8  and 9 ). In addition, we demonstrated that conjugation of ubiquitin to CT-c-Myb in this assay was significantly reduced compared to FL-c-Myb or NT1-c-Myb (Figure 10 ). Despite the lack of direct evidence that only the ubiquitinated form of FL-c-Myb is degraded by the 26S proteasome, these experiments showed a good correlation between less ecient posttranslational modi®cation of CT-c-Myb by ubiquitin in vitro and increased protein half-life in vivo. Therefore, we speculate that increased stability of the COOHterminally truncated protein is a consequence of less ecient ubiquitination and, therefore, reduced targeting for rapid degradation by the 26S proteasome complex.
At present there is little known about the protein determinants which render them intrinsically instable. Rogers et al. (1986) performed a computer analysis of common structural motifs in several short lived protein and identi®ed the presence of internal sequences named PEST that are rich in proline (P), glutamic acid (E) and/or aspartic acid, serine (S) and threonine (T). To determine the existence of such sequences in murine cMyb we employed the algorithm PEST-FIND, which scores all sequences of ten or more amino acids residues that are enriched in P, E, S, and T and anked by the basic residues R, K, or H and combines these results with the predicted hydrophilicity of potential PEST sequence (Rogers et al., 1986) . In the recent years PEST sequences were linked to the instability signal on many short-lived proteins degraded by the ubiquitin-26S proteasome pathway and their deletion signi®cantly increased stability of several (Kornitzer et al., 1994; Tsurumi et al., 1995; Yaglom et al., 1995; Lin et al., 1996) . Our search located three regions in murine c-Myb that had a positive PEST-score (PEST 1, 2 3; see Figure 11a ). PEST 3 may potentially represent an`instability' determinant, recognized by the ubiquitin-26S proteasome system, because its removal due to virus integration in the central portion of the c-myb locus results in a more stable protein (Figure 11b ). It is relevant in this respect to note that PEST 3 (unlike PEST 1 and PEST 2 which contain several amino acids changes when compared between dierent species) is highly conserved among c-Myb proteins of higher vertebrates (for a comparison of this region in murine, human and chicken Myb see Figure 11c ) strengthening its potential role in protein function. Recently, Aziz et al. (1995) described the negative regulation of c-Myb transactivation activity through phosphorylation of serine 528 located in the PEST 3 sequence, because a point mutation which converted this serine to alanine resulted in increased transactivation. An attractive explanation for this eect would be that the stabilization of the mutant protein results in increased transactivation potential of mutated c-Myb protein. In fact, PEST sequences rich in proline and serine residues contain many potential sites for protein kinases and phosphorylation dependent degradation of target proteins by the 26S proteasome was already described (Kornitzer et al., 1994; Yaglom et al., 1995; Lin et al., 1996) . Interestingly, there is a striking correlation between the increase in half-life of the COOHterminally truncated c-Myb (2.8-fold on average) in this paper and the increase in transactivation activity (2 ± 4 fold) by similarly truncated proteins as reported by others (Sakura et al., 1989 Nakagoshi et al., 1992 Dini and Lipsick, 1993) . On account of this, we hypothesize that the observed increase in the transactivation capacity of some COOH terminally truncated mutants previously studied could at least in part be explained by an extended protein half-life. More extensive experiments aimed at linking increased transactivation with increased stability will be required in future studies to address this issue.
Materials and methods
Cells and Viruses
The murine myeloid leukemia cell line M1 (Liebermann and Homan-Liebermann, 1989 ) was maintained in RPMI 1640 medium supplemented with 10% heat-inactivated horse serum. Murine amphotropic GP+envAM12 (Markowitz et al., 1988a) and ecotropic GP+E-86 (Markowitz et al., 1988b) packaging cell lines and murine leukemic cell lines 30A2-1-2, 30A2-3-12, 30A2-3-14 and R1-4-11 (Wol et al., 1991; Mukhopadhyaya and Wol, 1992) were maintained in DMEM containing 10% fetal bovine serum (FBS). The murine leukemic cell line NFS60 (Weinstein et al., 1986) was maintained in RPMI 1640 medium supplemented with 10% FBS and 10% WEHI-3B conditioned medium as a source of IL-3 (Ymer et al., 1985) .
Recombinant retroviruses were prepared as previously described (Bies et al., 1995) by transfecting plasmids LXSN (Miller and Rosman, 1989) , LFLmybSN, LNT1mybSN, LNT2mybSN and LCTmybSN into the amphotropic packaging cell line GP+envAM12 by the calcium phosphate method. After 48 h, conditioned medium containing virus was used to infect the ecotropic packaging cell line GP+E-86 in the presence of 4 mg/ml of Polybrene (Sigma). Infected cells were selected by culturing in medium containing 400 mg/ ml G418 (GIBCO). Selected cells producing recombinant retroviruses were treated with mitomycin C (10 ng/ml; Sigma) and used to infect M1 cells by cocultivation. The infected M1 cells were subsequently selected for resistance to G418 (500 mg/ml).
Northern (RNA) analysis
Total RNA was prepared from 3 ± 5610 6 cells using TRIzol reagent (GIBCO) as described in the manufacturer's instructions. Ten mg samples of total RNA were electrophoresed on a 1.2% agarose gel containing formaldehyde (0.7%) and blotted onto a nylon membrane (Nytran, Schleicher & Schuel) . Membranes were u.v. crosslinked using a Stratalinker 1800 (Stratagene) prior to hybridization. The following hybridization probes were labeled using a random priming kit (GIBCO): a 2.0 kb NcoI fragment of c-myb (Bender and Kuehl, 1986) , and rat GAPD (glyceraldehyde-3-phosphate-dehydrogenase) cDNA (Fort et al., 1985) .
Metabolic labeling of protein, immune precipitation and gel electrophoresis
To detect the expression of c-Myb proteins, 1610 7 cells were starved for 15 min in 1 ml of methionine/cysteine-free medium and then metabolically labeled for 45 min with 400 mCi Trans 35 S-label (ICN), washed free of radioactive amino acids (pulse) and incubated in the prewarmed RPMI 1640 medium supplemented with 10% horse serum (chase). At indicated time points the cells were disrupted in cold lysis buer and immunoprecipitated with rabbit antiserum raised against the bacterial fusion protein GST-c-Myb(I) as described previously . All precipitates were electrophoresed under reducing conditions on an 8% polyacrylamide gel and visualized by¯uorography. Quantitative analyses of dried gels were performed on a Phosphoimager 425 using IMAGEQUANT software (Molecular Dynamics) and the half-lives of the proteins (t 1/ 2 ) were calculated using the formula t 1/2 = (0.6936t) /ln(N t / N 0 ), as described previously (LuÈ scher and Eisenman, 1988) .
Treatment with protease inhibitors
Protease inhibitors were added during the last 15 min of the pulse and kept at the indicated concentration during the entire chase. The peptide aldehydes, ALLN (N-acetyl-L-leucinyl-L-leucinyl-norleucinal) and ALLM (N-acetyl-Lleucinyl-L-leucinyl-methioninal); E-64d (2S, 3S-t-epoxysuccinyl-L-leucylamido-3-methyl-butane ethyl ester) (Sigma) and BAPTA/AM (Calbiochem) lactacystin (from EJ Corey, Harvard University) were dissolved in DMSO. Chloroquine and EGTA (Sigma) were dissolved in PBS and DMSO was added to the cell culture medium in every instance including a control without inhibitors.
Construction of retroviral vectors
The construction of retroviral vectors expressing FL-cMyb, NT1-c-Myb and CT-c-Myb was described previously (Bies et al., 1995) . To prepare a vector expressing NT2-cMyb, we ampli®ed cDNA from total RNA (tumor R1-4-15; Mukhopadhyaya and Wol, 1992) by reverse transcription and DNA ampli®cation as described previously (Bies et al., 1995) , using the following oligonucleotides; 5'-CCAATGGTATCCCGCCTG-3'-sense Friend strain FB29 MuLV gag (nucleotide 1195 to 1212) Perryman et al., 1992) and 5'-CTGGAAGCTCGTGGCCACTG-3'-antisense c-myb (nucleotide 890 to 909) (Bender and Kuehl, 1986 ). The resulting gag-myb fragment was subcloned into pCR1000 (Invitrogen Corp.) yielding pCRNT2. pCRNT2 was digested with NotI and EcoRI, and the excised 0.7 kb fragment was subcloned into pBlueSKII + (Stratagene) yielding pBNT2. To complete the gene, the remaining COOH-terminal part of c-myb was digested from p3ZMmb (Bender and Kuehl, 1986 ) using NcoI and EcoRI and the 1.4 myb fragment was subcloned into pBNT2 creating pBNT2myb. A retroviral vector expressing NT2-c-Myb was prepared by digesting the NotI ± NcoI fragment from pBNT2myb and converting both ends of this fragment to BamHI using phosphorylated linkers. The resulting fragment was subcloned into pLXSN (Miller and Rosman, 1989 ) yielding pLNT2-c-mybSN.
Preparation of cytoplasmic extracts for ubiquitination analyses
M1 cells were washed twice in ice cold isotonic PBS, resuspended in two volumes of hypotonic solution (20 mM N -2 -hydroxyethylpiperazine -N' -2 -ethanesulfonic acid [HEPES]-NaOH [pH 8], 10 mM KCl, 1 mM dithiothreitol, 0.5 mM MgCl 2 ), and disrupted by Dounce homogenization on ice for 3 min. The cell lysates were clari®ed by centrifugation at 30 000 g for 30 min followed by centrifugation at 100 000 g for 6 h to deplete the proteasome (S100) (Palombella et al., 1994) .
In vitro translation of c-Myb proteins and ubiquitination assay
The plasmids pBFLmyb, pBNT1myb and pBCTmyb were transcribed and translated in vitro using a TNT T3/T7 Coupled Rabbit Reticulocyte Lysate (RRL) System (Promega) in the presence of [ 35 S]methionine or complete amino acid mixture according to the manufacturer's protocol. In vitro translated c-Myb proteins were incubated with M1 (S100) cytoplasmic extract (70 mg) in 100 ml of reaction buer (40 mM Tris-HCl pH 7.6, 2 mM DTT, 10 mM KCl, 5 mM MgCl 2 , 1 mM ATP-g-S) with or without bovine ubiquitin (1 mg/ml; Sigma). The conjugation reactions were incubated for the indicated times at 378C in the presence of a protease inhibitor cocktail (Complete TM , Boehringer) and stopped by boiling in SDS ± PAGE loading buer. The products were resolved by SDS ± PAGE and visualized by¯uorography or Western blotting.
Immunoblot analysis
In vitro translated FL-c-Myb protein was immunoprecipated with rabbit anti-GST-c-Myb(I) polyclonal serum and immune complex was ubiquitinated in vitro as described previously. Ubiquitin-modi®ed protein products were separated by sodium dodecyl sulfate (SDS) ± polyacrylamide gel electrophoresis (PAGE) and transferred electrophoretically to Immobilon membranes (Millipore). The membranes wre incubated with monoclonal anti-cMyb typeII (UBI) or anti-ubiquitin (Zymed) antibodies and immunostained using ECL TM Western blotting protocol (Amersham).
